Innoviva (INVA) Revenue Growth (3y) (2014 - 2026)
Innoviva (INVA) Revenue Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,719.23 Bn | 65,718.94 Bn | - | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.85 Bn | 467.06 Bn | 1.35 Bn | 50.07% |
| 5 | Vertex Pharmaceuticals | 122.29 Bn | 115.04 Bn | 2.59 Bn | 7.94% |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.28 Bn | 3.31 Bn | 4.47% |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | 79.44% |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.47 Bn | 959.66 Mn | 54.05% |
| 10 | Innoviva | 1.61 Bn | 1.00 Bn | 75.83 Mn | 275.76% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 275.76% |
| Dec 31, 2025 | 1.07% |
| Sep 30, 2025 | 3.77% |
| Jun 30, 2025 | 190.09% |
| Mar 31, 2025 | 241.52% |
| Dec 31, 2024 | 7.69% |
| Sep 30, 2024 | -2.07% |
| Jun 30, 2024 | 231.67% |
| Mar 31, 2024 | 16.68% |
| Dec 31, 2023 | 44.73% |
| Sep 30, 2023 | 36.31% |
| Jun 30, 2023 | -67.04% |
| Mar 31, 2023 | -71.37% |
| Dec 31, 2022 | -75.99% |
| Sep 30, 2022 | 59.24% |
| Jun 30, 2022 | -59.98% |
| Mar 31, 2022 | -65.71% |
| Dec 31, 2021 | -76.86% |
| Sep 30, 2021 | 66.40% |
| Jun 30, 2021 | -65.57% |